Product Description
Mechanisms of Action: Vaccine
Novel Mechanism: No
Modality: Vaccine
Route of Administration: Intramuscular
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Adimmune
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 4: Influenza, Human|Kidney Failure, Chronic
Phase 3: Influenza, Human
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
2016-001557-41 | P3 |
Completed |
Influenza, Human |
2017-09-05 |
|
ADIMQIS20160328 | P3 |
Completed |
Influenza, Human |
2017-07-12 |
25% |
A-BR-101-139 | P4 |
Unknown status |
Influenza, Human|Kidney Failure, Chronic |
2014-06-01 |
|
FLU12T13A | P4 |
Completed |
Influenza, Human |
2012-08-01 |